JVIR, SIR Foundation Honor Best Research Published in 2019

The Journal of Vascular and Interventional Radiology (JVIR)—the Society of Interventional Radiology’s (SIR’s) peer-reviewed scientific journal—announced the 2019 JVIR Editor’s Best awards in the May issue of the journal, published online today. The annual awards, supported by SIR Foundation, were chosen by the editor after a comprehensive editorial board review of all papers submitted to JVIR during the prior year.

2019 JVIR EDITOR’S AWARD FOR OUTSTANDING CLINICAL STUDY

Belinda A. Mohr, Ph.D., was honored with the award for outstanding clinical research paper for “Clinical and Economic Benefits of Stent Grafts in Dysfunctional and Thrombosed Hemodialysis Access Graft Circuits in the REVISE Randomized Trial.”

In citing why this paper stood out, JVIR Editor-in-chief Ziv J Haskal, M.D., FSIR, said, “The analysis adds to the growing base of rigorous economic assessments of our interventional therapies. Hemodialysis costs billions of dollars in America. Our growing number of prospective controlled IR-led trials, such as in end-stage renal disease, allow this very type of essential research to help define the societal value of interventions for our patients.”

2019 JVIR EDITOR’S AWARD FOR OUTSTANDING LABORATORY INVESTIGATION

Yuchen Huo, MA, of the University of California San Diego, was honored with the award for outstanding laboratory investigation for “Stress Conditions Induced by Locoregional Therapies Stimulate Enrichment and Proliferation of Liver Cancer Stem Cells.”

“The downstream immunologic effects of thermal and transcatheter oncological treatments are being methodically fleshed out in the IR literature,” said Haskal. “One aspect is the under-recognized potential stimulatory effect of locoregional HCC treatments which might risk promulgating HCC stem cell proliferation, lessening overall cancer outcomes. This study described and quantified this very effect and defined a pathway for potentially suppressing it.”

Haskal, a professor with the department of radiology and medical imaging at the University of Virginia Health System in Charlottesville, also recognized the authors of an additional 12 clinical and five laboratory papers for their contributions. “In my decade as editor, this year marked a remarkably rich and diverse one for interventional radiologic research,” noted Haskal.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”